(Q34224541)

31 July 2017

1 reference

title

Lipid-lowering interventions in managed care settings (English)

1 reference

31 July 2017

Fox J

1

1 reference

31 July 2017

Jones K

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

American Journal of Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

110 Suppl 6A

1 reference

31 July 2017

page(s)

24S-30S

1 reference

A means to an end: an overview of a hyperlipidemia outcomes management program

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Choice of cost-effectiveness measure in the economic evaluation of cholesterol-modifying pharmacotherapy. An illustrative example focusing on the primary prevention of coronary heart disease in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Barriers and facilitators to providing common preventive screening services in managed care settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Secondary prevention of coronary heart disease in primary care: a healthy heart initiative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Use of Lipid Drugs With Acute Myocardial Infarction Patients: An Examination of Physician Prescribing Behaviors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Inadequate treatment with HMG-CoA reductase inhibitors by health care providers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

An intervention to increase physicians' use of adherence-enhancing strategies in managing hypercholesterolemic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Effect of training and a structured office practice on physician-delivered nutrition counseling: the Worcester-Area Trial for Counseling in Hyperlipidemia (WATCH).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Disease management for chronic congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Implementing quality assurance programs in multigroup practices for treating hypercholesterolemia in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Lifestyle modification program in management of patients with coronary artery disease: the clinical experience in a tertiary care hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). The SHIP Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Pharmaceutical cost containment and innovation in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Managed care pharmacy, socioeconomic assessments and drug adoption decisions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Drug formularies--good or evil? A view from a managed care provider.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

A randomized controlled trial of a physician-directed treatment program for low-income patients with high blood cholesterol: the Southeast Cholesterol Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900675-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(01)00675-1

1 reference

31 July 2017

1 reference